Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors

Inclusion Criteria: * Histologically confirmed advanced metastatic solid tumor * Ineligible to receive or progressed on standard of care therapies * Measurable or non-measurable disease per modified RECIST * Gallbladder must be in situ on screening ultrasound * ECOG Performance Status of 0 to 2 * Life expectancy of 6 months or more as determined by the investigator * Adequate organ and hematologic function as evidenced by laboratory studies prior to randomization * Men and women 18 years or older Exclusion Criteria: * Uncontrolled CNS metastases * Known history of prior cholecystitis, prior biliary procedure or prior or ongoing biliary disease * Radiation therapy within 14 days prior to randomization * Peripheral neuropathy \> Grade 1 per CTC AE v.3 * Currently or previously treated with AMG 706 or other VEGF inhibitors such as SU11248 (sunitinib), PTK787 (vatalanib), AZD2171, BAY 43-9006 (sorafenib), ZD6474 (vandetanib) * Previous treatment with bevacizumab is allowed if at least 6 weeks have elapsed from the last dose of bevacizumab to the date of randomization * Any anti-coagulant therapy within 7 days prior to randomization; low dose heparin and warfarin for prophylaxis against central venous catheter thrombosis is allowed * Less than 30 days have elapsed since participation in an investigational drug/device study or currently receiving investigational treatments * History of arterial or venous thrombosis within 1 year prior to randomization * History of bleeding diathesis or bleeding within 14 days of randomization * MI, CVA, TIA, PTCA/stent, CHF, Grade 2 or greater PVD, uncontrolled arrhythmias or unstable angina within one year prior to randomization * Uncontrolled HTN defined by a resting BP of \>150/90 mmHg * Surgery: major surgical procedure within 4 weeks or 28 days prior to randomization; minor surgical procedure, placement of access device or fine needle aspiration within 7 days of randomization; planned elective surgery while on study * Non-healing or open wound, ulcer or fracture * Known ongoing or active infection * Known (+) for HIV, Hep C or Hep B surface antigen * Known chronic hepatitis * Known history of allergy or hypersensitivity to AMG 706 or any of its components * Pregnant, ie, (+) b-HCG; breastfeeding